The following antibodies were used (from BioLegend):
CD4-APC-Cy7 (clone OKT4),
CD8-PerCp-Cy5.5 (clone SK1),
TIM-3-BV510 (clone F38-2E2), CD39-FITC or APC-Cy7 (clone A1), CD95-PE (clone DX2), CD3-PacBlue (clone HIT3a), PD-1-BV421 (clone EH12.2H7), and
CD3-PE (clone HIT3a); (from eBioscience):
PD-1-PE-Cy7 (clone eBio J105), LAG-3-PE (clone 3DS223H),
CD45RO-PE-Cy7 (clone UCHL1), and
CD45-PerCp-Cy5.5 (clone HI30); (from BD):
CD45RA-FITC or BV711 (clone HI100), CCR7-BV421 (clone 150503), CD122-BV510 (clone Mik-β3), CD62L-BV605 (clone DREG-56),
CD4-BUV395 (clone SK3), and
CD8-BUV805 (clone SK1).
The anti–CD19-28z CAR antibody was provided by B. Jena and L. Cooper, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX. The anti–HA-28z CAR antibody was provided by the National Cancer Institute, Frederick, MD. Each was conjugated with Dylight288 and/or 650 antibody labeling kits (Thermo Fisher).
Gennert D.G., Lynn R.C., Granja J.M., Weber E.W., Mumbach M.R., Zhao Y., Duren Z., Sotillo E., Greenleaf W.J., Wong W.H., Satpathy A.T., Mackall C.L, & Chang H.Y. (2021). Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America, 118(30), e2104758118.